Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension.

Journal: Circulation. Genomic and precision medicine
Published Date:

Abstract

BACKGROUND: Patients with pulmonary hypertension (PH) are classified based on disease pathogenesis and hemodynamic drivers. Classification informs treatment. The heart failure biomarker NT-proBNP (N-terminal pro-B-type natriuretic peptide) is used to help inform risk but is not specific to PH or sub-classification groups. There are currently no other biomarkers in clinical use to help guide diagnosis or risk.

Authors

  • Niamh Errington
    National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).
  • Li Zhou
    School of Education, China West Normal University, Nanchong, Sichuan, China.
  • Christopher J Rhodes
    National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).
  • Yiu-Lian Fong
    Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ (Y.-L.F., T.J.).
  • Lihan Zhou
    MiRXES Lab, Singapore, Republic of Singapore (Li Zhou, Lihan Zhou, C.H.).
  • Sokratis Kariotis
    Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore (S.K., D.W.).
  • Eileen Harder
    Brigham and Women's Hospital and Harvard Medical School, Boston, MA (E.H., A.W.).
  • Aaron Waxman
    Brigham and Women's Hospital and Harvard Medical School, Boston, MA (E.H., A.W.).
  • Timothy Jatkoe
    Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ (Y.-L.F., T.J.).
  • John Wharton
    National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).
  • A A Roger Thompson
    Division of Clinical Medicine, The University of Sheffield, United Kingdom (A.A.R.T., R.C., D.G.K.).
  • Robin A Condliffe
    Division of Clinical Medicine, The University of Sheffield, United Kingdom (A.A.R.T., R.C., D.G.K.).
  • David G Kiely
    Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Luke S Howard
    National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).
  • Mark Toshner
    Papworth NHS Foundation, Cambridge, United Kingdom (M.T.).
  • Cheng He
    Guangdong Provincial Key Laboratory of Brain-inspired Intelligent Computation, Department of Computer Science and Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
  • Dennis Wang
    Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Martin R Wilkins
    National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).
  • Allan Lawrie
    Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, United Kingdom (P.M.H., A.L.).